View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 31, 2011

Marshall Reports NV-128 Pre-Clinical Study Results

Marshall Edwards has announced the pre-clinical study results of NV-128 in chemotherapy-resistant ovarian cancer stem cells. The study demonstrated that NV-128 can specifically target the mitochondria in patient-derived ovarian cancer stem cells to induce cell death in chemo-resistant

By cms admin

Marshall Edwards has announced the pre-clinical study results of NV-128 in chemotherapy-resistant ovarian cancer stem cells.

The study demonstrated that NV-128 can specifically target the mitochondria in patient-derived ovarian cancer stem cells to induce cell death in chemo-resistant cell population.

Previous studies conducted at Yale University, US, showed that NV-128 is able to inhibit tumour growth in an ovarian cancer animal model without inducing significant toxicity.

It found that once administered, NV-128 is demethylated in vivo to NV-344, its active metabolite, which has been shown to be more potent than NV-128 in pre-clinical research studies.

The company said it plans to complete the required pre-clinical studies of NV-344 to submit an Investigational New Drug application to the US Food and Drug Administration by the first quarter of 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology